Powered By
Key breast cancer drug developments in early 2026 focus on targeted therapies for metastatic and high-risk disease, including the approval of Imlunestrant (Inluriyo), the FDA breakthrough designation of Zovegalisib (RLY-2608) for PIK3CA-mutated cancers, and promising results for Atirmociclib.
Key trends include next-generation oral SERDs and antibody-drug conjugates (ADCs).
CVS Health
Key Drug Developments (2026)
Imlunestrant tosylate (Inluriyo): Approved by the MHRA (UK) in Feb 2026 for… read more
Dr Makis credentials:
Dr. William Makis is a Canadian physician with extensive credentials in immunology, radiology, and oncology.
He earned a four-year undergraduate degree in Immunology from the University of Toronto, where he was a top scholarship recipient.
He obtained his Medical Degree (MD) from McGill University School of Medicine in 2005, one of Canada's most prestigious medical institutions.
He completed specialized residency training in Nuclear Medicine at McGill University, focusing on advanced imaging techniques and radiopharmaceutical applications.
Dr. Makis is board-certified in Nuclear Medicine and is a board-certified nuclear radiologist with expertise in theranostics, cancer imaging, and targeted radionuclide therapy.
He has over 14 years of experience in nuclear medicine, radiology, and oncology, including clinical work at the Cross Cancer Institute in Edmonton, Alberta, where he contributed to one of North America’s largest Targeted Radionuclide Therapy Cancer Clinics.
He has diagnosed over 10,000 cancer patients using advanced diagnostic tools such as PET/CT.
He has authored over 100 peer-reviewed publications in international medical journals, with research focused on nuclear medicine, PET/CT imaging, and targeted radionuclide therapy.
He has served as an Assistant Clinical Professor in the Department of Radiology and Diagnostic Imaging at the University of Alberta and as a Clinical Lecturer in the Department of Radiology at the University of Manitoba, contributing to academic instruction and radiology research.
Dr. Makis has also held leadership roles, including Director of the Department of Nuclear Medicine at Brandon Regional Health Centre and a founding board member at The Wellness Company.
He is recognized as a leading expert in theranostics and has been involved in innovative cancer treatment protocols, including the use of repurposed drugs like Ivermectin and Mebendazole in cancer therapy.
What are the key breast cancer drug developments in early 2026?
Early 2026 is shaping up to be an exciting time for breast cancer treatment! Here's a summary of the most notable developments:
New Approvals & Designations
- Imlunestrant (Inluriyo): Approved in the UK (Feb 2026) for ER+, locally advanced or metastatic Show Full Answer
@A MyBCTeam Member why are you so hostile against this man? I have been taking his protocol since September 2024 at low dose then high dose starting Nov/Dec 2025 with no conventional treatment for stage 3 grade 3 BC and so far no recurrence, I think that upon it self is pretty amazing. We all have different opinions on repurposed drugs but so far they are working for me and that is all that matters. Sending hugs as I know you mean well ❤️
Thankfully the medical research has been thoroughly checked, we really need to listen to our Oncology Team.....as they have trained for years...
Any new information has to be run through the same health process.
@A MyBCTeam Member I am now a patient at City of Hope Duarte, CA. I am seeing a oncologist that has been working with Dr Peter P. Lee on this clinical trial.
I believe this is why I finally found a oncologist to take my case.
The primary initiative at City of Hope is a Phase I/II clinical trial investigating the combination of ivermectin with balstilimab (an anti-PD-1 immune checkpoint inhibitor) for patients with metastatic triple-negative breast cancer
1.
Trial Design: The study enrolls patients who have progressed on prior therapies. It uses a dose-escalation design to determine the safe and effective dose of ivermectin (ranging from 30 mg to 60 mg daily) when combined with balstilimab
1.
Mechanism of Action: Preclinical research led by Dr. Peter P. Lee at City of Hope demonstrated that ivermectin induces immunogenic cell death (ICD) in breast cancer cells. This process recruits T-cells into the tumor microenvironment, effectively converting "cold" tumors (which do not respond to immunotherapy) into "hot" tumors that can be attacked by the immune system
Synergy: Studies showed that ivermectin alone or anti-PD1 alone had limited efficacy in mouse models, but the combination resulted in synergistic tumor regression and complete responses in a significant number of subjects
Current Status: As of the 2025 ASCO Annual Meeting, the trial had accrued patients and completed dose levels 1 and 2 with a favorable safety profile, showing no serious adverse events attributed to the drug combination
1. Preliminary results indicated a clinical benefit rate of 37.5% in a heavily pretreated population, warranting further investigation
PS. I should have said Dr Makis is opening a clinic in Florida with the help of Governor Ron DeSantis. Governor DeSantis issued a medical license for pre clinical trials to Dr Makis which involve Ivermectin and Mebendazole.
Continue with Facebook
Continue with Email
Join
Your Privacy Choices
